Project Grant R01AI198293
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital $151,040 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on December 4, 2025, to support a project extending through July 31, 2028. This Project Grant funds basic science research investigating the regulatory mechanisms of a small regulatory RNA (sRNA) designated BECO in Pseudomonas aeruginosa, a gram-negative bacterium that causes serious...
- Federal Grant Award Summary Boston Children's Hospital received an $800,557 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 19, 2026, with completion targeted for January 31, 2031. The grant supports investigator-initiated biomedical research to identify mechanisms by which the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host immune...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $122,472 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Children's Hospital on August 13, 2025, with a completion date of July 31, 2027. This award supports investigator-initiated research aimed at elucidating the molecular mechanisms underlying the activation and regulation of the NLRP3 inflammasome, a critical component of the...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a $267,000 Project Grant on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the mechanisms underlying messenger RNA-lipid nanoparticle (mRNA-LNP) vaccine efficacy. The research, to be completed by May 31, 2028, focuses on understanding how mRNA-LNP vaccines elicit immune responses despite delivering...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 24, 2025, with a completion date of June 30, 2027. The award funds structural research aimed at determining the high-resolution three-dimensional structure of the full-length nucleocapsid (N) protein of Severe Acute Respiratory Syndrome Coronavirus 2...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital $445,000 through the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct investigator-initiated biomedical research on novel immunoregulatory mechanisms modulating myeloid trained immunity following organ transplantation. The project, which commenced February 18, 2026, and extends through January 31, 2031, focuses on developing therapeutic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $522,524 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, with a completion date of June 30, 2030. This award supports research into the mechanism of inflammation in adenosine deaminase 2 (ADA2) deficiency (DADA2), a rare inborn error of immunity characterized by systemic inflammation, vascular involvement,...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a $889,904 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective June 10, 2026, with completion targeted for May 31, 2031. This research initiative will deliver mechanistic understanding of how the integrin α4β7 protein mediates leukocyte rolling and firm adhesion during extravasation, with particular focus on improving...
- Federal Grant Award Summary Boston Children's Hospital received a $534,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning June 1, 2026, and concluding May 31, 2028. The project develops novel delivery systems and therapeutic proteins capable of reversing botulinum neurotoxin (BoNT) intoxication within motor neurons. The research addresses a critical gap in biodefense and...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston University Medical Campus a $245,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of May 1, 2026 through April 30, 2028. This research initiative focuses on identifying the viral and cellular mechanisms that enable non-canonical translation of pneumovirus messenger RNAs (mRNAs), particularly Respiratory Syncytial Virus (RSV)...
Boston Children's Hospital received a $794,886 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 11, 2026, with completion targeted for May 31, 2031. The research investigates the role of endogenous chimeric messenger RNA (mRNA)-encoded gasdermin D (GSDMD) fusion proteins in innate immune responses, specifically pyroptosis—a form of programmed inflammatory cell death critical to host defense against infection. The project employs an innovative long-read direct RNA sequencing pipeline to discover and characterize native chimeric mRNA species in mammalian cells, with particular focus on the GSDMD:TMEM106A fusion protein identified in murine macrophages and its putative human counterpart, GSDMD:S100A6. The research will generate scientific knowledge regarding alternative RNA processing mechanisms that regulate GSDMD-mediated pyroptosis and cytokine release, moving beyond the conventional understanding of post-translational protein control. Functional studies will establish the critical role of identified fusion proteins in immune cytokine secretion and protective immunity against bacterial infection, with potential translational applications demonstrated through in vivo delivery of fusion protein mRNA. The project will produce peer-reviewed research publications, characterized biological specimens, and methodological advances in direct RNA sequencing technology applicable to future immunological and infectious disease research.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $794.9k | 6/12/26 |